Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Date:11/28/2008

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 2015 Forskere kan ... på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab for ... i Wien .  ... forskere og videnskabsmænd foretaget af Ludwig Boltzmann ... for sundhedsvidenskaben manglen på incitamenter til at ...
(Date:7/2/2015)... BETHESDA, Md. , July 2, 2015  Spherix ... committed to the fostering and monetization of intellectual property, ... matter of Spherix Incorporated v. Verizon Services Corp. ... States District Court for the Eastern District of ... Order on July 1, 2015 interpreting certain key claims ...
(Date:7/2/2015)... ... 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), ... today the acquisition of Turner Medical, Inc ., thus becoming a global ... the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product ...
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... GAINESVILLE, Fla. --- Algae is a livid green giveaway of ... that action in tiny particles that would turn different colors ... poor health in the blood. , Now, University of Florida ... clear a major hurdle to creating such "smart dust.",The feat, ...
... studies illustrating the value of in situ mid IR reaction monitoring ... ... Columbia, MD (PRWEB) January 18, 2009 -- METTLER TOLEDO invites ... Chemistry Using Real-Time In Situ FTIR presented by Dr. Jennifer ...
... 16 N-Viro International Corporation,(OTC Bulletin Board: NVIC), ... technologies to convert various types of waste into,beneficial ... Fuel(TM), has satisfied guidelines set forth by the ... alternative energy,source that may be utilized in commercial ...
Cached Biology Technology:Researchers: Molecular forklifts overcome obstacle to 'smart dust' 2Researchers: Molecular forklifts overcome obstacle to 'smart dust' 3N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency 2N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency 3N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency 4
(Date:6/17/2015)... June 17, 2015  Crossmatch™, a leading provider ... its U.are.U ® 4500 fingerprint readers have ... Eateries, Inc., a San Jose, CA ... increase security, improve accountability and reduce fraud at ... non-repudiable identity confirmation for employee sign in and ...
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
(Date:6/16/2015)... -- Fingerprint Cards (FPC) raises the revenue guidance ... to at least 340 MSEK to that it will amount ... market growth and orders received the revenue guidance for 2015 ... 2015 will exceed 1,500 MSEK to an updated guidance that ... Due to receipt of orders of touch fingerprint sensors ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... way for improved study of hepatitis C virus by ... of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted ... report by Lázaro et al, "Hepatitis C virus replication ... in the February issue of The American Journal of ...
... reduces the risk of acquiring HIV in young African men, ... Chicago professor of epidemiology Robert Bailey. , The study is ... , Researchers conducted a clinical trial enrolling 2,784 HIV ... Kisumu, Kenya, where an estimated 26 percent of uncircumcised men ...
... from preterm birth are staggering. In Canada, outlays for ... be almost $2 billion per year. In a 5-year, ... to mothers who had entered premature labor led to ... the study are reported in the January issue of ...
Cached Biology News:New culture method for hepatitis C virus uses primary hepatocytes and patient serum 2Circumcision: A proven strategy to prevent HIV 2